Lifelong volunteer finds joy, connection in retirement through giving back
Wong’s vision for the future is ambitious yet practical. He hopes to make volunteering more accessible and inclusive, ...
The Andalusia Star-News1d
Covington Cty. Alzheimer’s Walk planned for Sunday, April 6
Covington County residents are invited to join the fight to end Alzheimer’s by participating in the Covington County Mini ...
European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
‘I wish I had known more’: Barbara Corcoran shares family’s Alzheimer’s journey and resources
For years, entrepreneur Barbara Corcoran has put her skills at the forefront of investing in optimistic businesses through ...
News4JAX2d
NBA will not keep All-Star mini-tournament for 2026, is 'back to the drawing board'
NEW YORK – The NBA will not bring back its All-Star Game mini-tournament next season. Commissioner Adam Silver said Thursday that the format used last month — a four-team tournament made up of 24 NBA ...
The 21st Legion Wargaming's 4th annual Battle to End Alzheimer’s event takes place on April 12-13
JC Watt shares his story on why he started this fundraiser for Alzheimer's and its new location at the Star Centre in Havre ...
Shark Tank’s Barbara Corcoran talks Alzheimer’s advocacy
If you’ve ever watched Shark Tank, you probably know Barbara Corcoran. On the show, she invests in businesses, but away from ...
Cassava Sciences Must Face Malicious Prosecution Lawsuit Over Alzheimer's Drug
NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by ...
BioSpace4d
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam
Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.
Cassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be Discontinued
Cassava said that it will discontinue all efforts to develop simufilam and expects to phase out the program by the end of the second quarter. Still, the biotechnology company said it has begun ...
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with ...